An Introduction to Pharmacovigilance
()
About this ebook
Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problems.
This introductory guide is designed to aid the rapid understanding of the key principles of pharmacovigilance. Packed full of examples illustrating drug safety issues it not only covers the processes involved, but the regulatory aspects and ethical and societal considerations of pharmacovigilance.
Covering the basics step-by-step, this book is perfect for beginners and is essential reading for those new to drug safety departments and pharmaceutical medicine students. The second edition is thoroughly revised and updated throughout and includes a new chapter on clinical aspects of pharmacovigilance.
Related to An Introduction to Pharmacovigilance
Related ebooks
Pharmacovigilance Medical Writing: A Good Practice Guide Rating: 4 out of 5 stars4/5Biological Drug Products: Development and Strategies Rating: 0 out of 5 stars0 ratingsNonclinical Safety Assessment: A Guide to International Pharmaceutical Regulations Rating: 0 out of 5 stars0 ratingsDocumentation of Clinical Trial Monitoring: A practical guide compliant with Good Clinical Practice Rating: 5 out of 5 stars5/5Drug Disposition and Pharmacokinetics: From Principles to Applications Rating: 0 out of 5 stars0 ratingsGlobal New Drug Development: An Introduction Rating: 0 out of 5 stars0 ratingsPredictive Approaches in Drug Discovery and Development: Biomarkers and In Vitro / In Vivo Correlations Rating: 0 out of 5 stars0 ratingsGood Clinical Practice Guide Rating: 5 out of 5 stars5/5Textbook of Pharmacoepidemiology Rating: 0 out of 5 stars0 ratingsPharmacogenomics in Clinical Therapeutics Rating: 0 out of 5 stars0 ratingsCase Studies in Modern Drug Discovery and Development Rating: 0 out of 5 stars0 ratingsA Practical Guide to Decontamination in Healthcare Rating: 0 out of 5 stars0 ratingsClinical Trial Design: Bayesian and Frequentist Adaptive Methods Rating: 0 out of 5 stars0 ratingsAntibacterial Agents: Chemistry, Mode of Action, Mechanisms of Resistance and Clinical Applications Rating: 0 out of 5 stars0 ratingsCareers with the Pharmaceutical Industry Rating: 0 out of 5 stars0 ratingsPharmacovigilance Rating: 0 out of 5 stars0 ratingsRisk-Based Monitoring and Fraud Detection in Clinical Trials Using JMP and SAS Rating: 0 out of 5 stars0 ratingsScientific Advice Meetings: A Guide to Successful Interactions with FDA, EMA and Beyond Rating: 0 out of 5 stars0 ratingsClinical Research A Complete Guide - 2021 Edition Rating: 0 out of 5 stars0 ratingsVaccine Development and Manufacturing Rating: 0 out of 5 stars0 ratingsPractical Pharmaceutical Engineering Rating: 0 out of 5 stars0 ratingsChemical Engineering in the Pharmaceutical Industry, Active Pharmaceutical Ingredients Rating: 0 out of 5 stars0 ratingsRandomized Clinical Trials: Design, Practice and Reporting Rating: 0 out of 5 stars0 ratingsCareers in Focus: Pharmaceuticals and Biotechnology, Third Edition Rating: 0 out of 5 stars0 ratingsPharmacopolitics: Drug Regulation in the United States and Germany Rating: 0 out of 5 stars0 ratingsQuality Systems and Controls for Pharmaceuticals Rating: 0 out of 5 stars0 ratingsFast Facts: Biosimilars Rating: 0 out of 5 stars0 ratingsContinuous Manufacturing of Pharmaceuticals Rating: 0 out of 5 stars0 ratingsHugo and Russell's Pharmaceutical Microbiology Rating: 0 out of 5 stars0 ratingsStatistical Issues in Drug Development Rating: 0 out of 5 stars0 ratings
Medical For You
The Lost Book of Simple Herbal Remedies: Discover over 100 herbal Medicine for all kinds of Ailment, Inspired By Dr. Barbara O'Neill Rating: 0 out of 5 stars0 ratingsWhat Happened to You?: Conversations on Trauma, Resilience, and Healing Rating: 4 out of 5 stars4/5The Vagina Bible: The Vulva and the Vagina: Separating the Myth from the Medicine Rating: 5 out of 5 stars5/5Adult ADHD: How to Succeed as a Hunter in a Farmer's World Rating: 4 out of 5 stars4/5The Little Book of Hygge: Danish Secrets to Happy Living Rating: 4 out of 5 stars4/5Gut: The Inside Story of Our Body's Most Underrated Organ (Revised Edition) Rating: 4 out of 5 stars4/5The Diabetes Code: Prevent and Reverse Type 2 Diabetes Naturally Rating: 4 out of 5 stars4/5Brain on Fire: My Month of Madness Rating: 4 out of 5 stars4/5The Emperor of All Maladies: A Biography of Cancer Rating: 5 out of 5 stars5/5Mating in Captivity: Unlocking Erotic Intelligence Rating: 4 out of 5 stars4/5Living Daily With Adult ADD or ADHD: 365 Tips o the Day Rating: 5 out of 5 stars5/5Mediterranean Diet Meal Prep Cookbook: Easy And Healthy Recipes You Can Meal Prep For The Week Rating: 5 out of 5 stars5/5Women With Attention Deficit Disorder: Embrace Your Differences and Transform Your Life Rating: 5 out of 5 stars5/5The Song of the Cell: An Exploration of Medicine and the New Human Rating: 4 out of 5 stars4/5Blitzed: Drugs in the Third Reich Rating: 4 out of 5 stars4/5Peptide Protocols: Volume One Rating: 4 out of 5 stars4/5This Is How Your Marriage Ends: A Hopeful Approach to Saving Relationships Rating: 4 out of 5 stars4/5Medical Billing and Coding For Dummies Rating: 4 out of 5 stars4/5"Cause Unknown": The Epidemic of Sudden Deaths in 2021 & 2022 Rating: 5 out of 5 stars5/552 Prepper Projects: A Project a Week to Help You Prepare for the Unpredictable Rating: 5 out of 5 stars5/5Herbal Healing for Women Rating: 4 out of 5 stars4/5ATOMIC HABITS:: How to Disagree With Your Brain so You Can Break Bad Habits and End Negative Thinking Rating: 5 out of 5 stars5/5The Invisible Rainbow: A History of Electricity and Life Rating: 5 out of 5 stars5/5Holistic Herbal: A Safe and Practical Guide to Making and Using Herbal Remedies Rating: 4 out of 5 stars4/5
Reviews for An Introduction to Pharmacovigilance
0 ratings0 reviews
Book preview
An Introduction to Pharmacovigilance - Patrick Waller
1
What is Pharmacovigilance and How Has it Developed?
Origins and Definition of Pharmacovigilance
In the beginning, there was thalidomide. The history of drug safety goes back further but, for practical purposes, the story of modern pharmacovigilance begins there.
In the late 1950s there was little, if any, regulation of medicines outside the USA (where thalidomide was not allowed on to the market), and their testing and development was almost entirely in the hands of pharmaceutical companies. In the case of thalidomide, unjustified claims of safety in pregnancy were made, and its use as a sedative and treatment for nausea and vomiting was targeted at pregnant women. The drug turned out to be a teratogen, producing a variety of birth defects but particularly limb defects known as phocomelia (Figure 1.1). Worldwide, about 10 000 babies were affected, particularly in Germany where the drug was first marketed. As phocomelia was otherwise a very rare congenital abnormality, a major increase in its incidence did not go unnoticed in Germany, but the cause was initially thought to be environmental. In 1961, a series of just three cases of congenital anomalies associated with thalidomide use in Australia was reported in The Lancet, the problem was finally recognised and the drug withdrawn from sale.
Photo of a child with thalidomide?induced phocomelia and limb defect.Figure 1.1 Child affected by thalidomide‐induced phocomelia.
At the beginning of the 1960s, publication of possible adverse effects of drugs in the medical literature was effectively the only mechanism for drawing attention to them. Thalidomide produced a non‐lethal but visible and shocking adverse effect, leading people to ask why so many damaged babies had been born before anything had been done? This question is central to subsequent developments. It is unlikely that we will ever be able to predict and prevent all the harms that may be caused by medicines, but limiting the damage to much smaller numbers is now achievable. Today we would expect to be able to identify an association between drug and outcome analogous to thalidomide and phocomelia after the occurrence of less than 10 cases, so at least three orders of magnitude more effectively than six decades ago.
The overriding lesson learnt from thalidomide was that we cannot just wait until a drug safety problem hits us. The thalidomide tragedy of the 1960s led directly to the initial development of the systems we have in place today, although it is only since the early 1990s that the term pharmacovigilance has become widely accepted.
Pharmacovigilance is defined by the World Health Organization as ‘The science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug‐related problems.’ There are other definitions but this very broad one seems to be the most appropriate because there is a clear implication that the process is one of risk management. This is a concept that is applicable to many aspects of modern life but, surprisingly, its explicit use in relation to pharmaceuticals is a fairly recent development.
Thalidomide is not merely of historical interest, as in recent years it has made a comeback on to the market in some countries but with very narrow indications and extensive safeguards. The reasons for this exemplify the point about risk management, as the risk of fetal malformation can be successfully managed by avoidance of the drug during pregnancy. It also demonstrates another concept that is central to the practice of pharmacovigilance – the balance of benefit and risk. Thalidomide has benefits in some diseases that are otherwise difficult to treat (e.g. refractory multiple myeloma) and these appear to outweigh the risk of fetal malformation if there is an effective pregnancy prevention scheme in place. A further point that thalidomide illustrates well – and which is relevant to many other drug safety issues – is that not everyone is at the same risk of a particular adverse effect. In this case, a substantial part of the population (including men and also women who are not of childbearing capacity) are not at risk of phocomelia.
Main Lessons Learned from Thalidomide
The thalidomide tragedy taught us many lessons:
The need for adequate testing of medicines prior to marketing.
The need for government regulation of medicines.
The need for reporting systems to identify the adverse effects of medicines.
The potential safety implications of unproven marketing claims.
Most medicines cross the placenta and this results in fetal exposure.
Avoidance of unnecessary use of medicines in pregnancy.
That some risks can be successfully minimised.
The ramifications of the thalidomide tragedy were manyfold, but the key lesson for the development of pharmacovigilance was that active systems for detecting hazards are needed. Within a few years this had been taken forward with the introduction of voluntary (or ‘spontaneous’) schemes for reporting of suspected adverse drug reactions (ADRs). These have stood the test of time as an alerting mechanism or early warning system, and are covered in more detail in Chapter 3.
Scope and Purposes of Pharmacovigilance
In the past, the process of pharmacovigilance has often been considered to start when a drug is first authorised for use in ordinary practice. Nowadays, it is more commonly considered to include all safety‐related activity beyond the point at which humans are first exposed to a new medicinal product.
The ultimate purpose of pharmacovigilance is to minimise, in practice, the potential for harm that is associated with all active medicines. Although data about all types of ADRs are collected, a key focus is on identifying and preventing those that are defined to be serious. This is generally defined as an ADR that meets at least one of the following criteria:
Fatal
Life‐threatening
Causes or prolongs hospitalisation
Results in long‐term disability
All congenital anomalies.
The definition of serious also allows the application of medical judgement, such that a reaction can be considered serious even if there is not clear evidence that one of the above criteria is met. Non‐serious reactions are important to individual patients and health professionals involved in their treatment, but they can usually be managed clinically and impact less on the balance of benefit and risk for individual products and on public health in general.
Thus, pharmacovigilance can be seen as a public health function in which reductions in the occurrence of serious harms are achievable through measures that promote the safest possible use of medicinal products and/or provide specific safeguards against known hazards. Pregnancy prevention in users of thalidomide is an example of such a safeguard; monitoring white blood cell counts to detect agranulocytosis (absent white blood cells) in users of the antipsychotic drug clozapine is another (see Chapter 7).
In order to minimise harms, there is first a need to identify and assess the impact of unexpected potential hazards. For most medicines, serious ADRs are rare, otherwise their detection would result in the drug not reaching (or being withdrawn from) the market. For products that do reach the market, serious hazards are seldom identified during pre‐marketing clinical trials because sample sizes are invariably too small to detect them. In addition, the prevailing conditions of clinical trials – selected patients, short durations of treatment, close monitoring and specialist supervision – usually mean that the frequency of ADRs will be underestimated relative to what will really occur in ordinary practice.
During pre‐marketing clinical development and research on new medicines, the aims of pharmacovigilance are rather different from the broad public health functions described here. In volunteer studies and clinical trials, there is a need to protect individuals exposed to experimental products (from which they may derive no benefit) from potential harm. There is also a need to gather information on risks (including the frequencies at which they happen) in order to make a provisional assessment of safety and to plan for post‐marketing safety development (see Risk Management Planning in Chapter 5).
Development of Pharmacovigilance
We next consider some of the most important examples of drug safety issues and discuss how they have affected the development of pharmacovigilance practice from the 1960s to the present day.
Practolol
In the early 1970s another drug safety disaster occurred; this was the oculo‐mucocutaneous syndrome, a multi‐system disorder, caused by practolol (Eraldin), a cardioselective beta‐blocker used to treat angina and hypertension. As in the case of thalidomide, several thousand individuals were permanently damaged before the association was recognised. The fundamental problem in this instance was a failure of timely identification, as despite having an early warning system in place, the system was dependent on doctors suspecting an association between drug and disease. Probably because of the unusual nature of the syndrome – dry eyes, skin rash and bowel obstruction – and a long latency period (averaging almost 2 years in respect of the onset of the most serious bowel manifestations), relevant cases were not reported until the association was identified in the medical literature. Around 3000 cases were then retrospectively reported to the UK Yellow Card spontaneous ADR reporting scheme (see Chapter 3), an example of the potential effect of publicity on ADR reporting. Interestingly, subsequent attempts to develop an animal model of practolol toxicity failed, indicating that the problem could not have been predicted from pre‐clinical studies.
Main Lessons Learned from Practolol
Some adverse effects are not predictable from pre‐clinical studies.
Spontaneous reporting schemes are not always effective at identifying new ADRs.
Health professionals may not be able to identify long latency effects and clinical manifestations not known to be related to other drugs as ADRs.
Additional, proactive and more systematic methods of studying post‐marketing safety are needed.
The overriding message from practolol was that spontaneous ADR reporting alone is insufficient as a means of studying post‐marketing safety. Thus, in the late 1970s various schemes designed to closely monitor the introduction of new drugs were suggested, but few implemented. The basic idea was that initial users of new drugs would be identified through prescriptions and monitored systematically rather than waiting for someone to recognise a possible adverse effect. The concept did come to fruition in New Zealand and in England in the late 1970s with the development of nationwide prescription‐event monitoring (PEM) programmes (see Chapter 3).
Benoxaprofen
The first drug studied by PEM in England was benoxaprofen (Opren), a non‐steroidal anti‐inflammatory drug (NSAID) which frequently produced photosensitivity reactions (i.e. rashes in light‐exposed areas). A published case series from Northern Ireland of five deaths related to hepatic and renal failure led to withdrawal of the drug in 1982, although the PEM study did not reveal any indication of these effects. Many of the patients who experienced serious ADRs with benoxaprofen were elderly; this was a result of reduced excretion of the drug as a consequence of renal impairment. Even though it is well‐recognised that many patients who use NSAIDs are elderly (e.g. for arthritis or chronic pain), benoxaprofen had not been adequately studied in this population prior to marketing. A reduction in the dosage recommendations for the elderly was implemented briefly, but benoxaprofen was withdrawn soon afterwards.
Because the usage of benoxaprofen took off rapidly after launch and an important adverse effect – photosensitivity reactions – was common, a large number of spontaneous reports were received in a short period of time, swamping the primitive computer systems then used and pointing to the need for purpose‐designed databases. The issue also illustrated the need for patients to be properly informed about possible ADRs and how to minimise the risk – in this case by avoiding exposure to the sun. It was therefore influential in moving towards the introduction of patient information leaflets, which became compulsory in the European Union (EU) during the